Statistics

Total Visits

Views
Phase II multicenter study to analyze the predictive value of fusion gene TMPRSS2-ETS assessed both in tumor and blood sample, as a marker of response to enzalutamide in patients with metastatic castration resistant prostate cancer (CRPC) pre-chemotherapy83

Select a period of time:

Number of views in the range

Views
Phase II multicenter study to analyze the predictive value of fusion gene TMPRSS2-ETS assessed both in tumor and blood sample, as a marker of response to enzalutamide in patients with metastatic castration resistant prostate cancer (CRPC) pre-chemotherapy16

Views

Views
October 20253
November 20251
December 20252
January 20260
February 20260
March 20269
April 20261
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States5
United Kingdom2
Australia1
Brazil1
Colombia1
Ecuador1
Finland1
France1
Honduras1
Jamaica1
 

Top cities views

Views
Canoas1
Helsinki1
Ibarra1
Jersey City1
Johannesburg1
Kingston1
Los Angeles1
Santiago de Cali1